Friday, June 24, 2016 5:01:00 AM PDT | VentureDeal
Baltimore, Maryland -- Biopharmaceutical technology company Centrexion Therapeutics has received $11.1 million in new venture capital debt funding, according to an SEC regulatory filing.
Centrexion is focused on developing a pipeline of non-opioid treatment for chronic pain. The company is utilizing both internal development and strategic in-licensing to hopefully create next-generation pain management treatments. Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds. A total of 61 investors participated in the offering.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
